Clinical and hormonal features of acromegaly in patients from a Ukrainian neuroendocrinology centre [Text] / O. Khyzhnyak [et al.] // Пробл. ендокринної патології. - 2019. - N 2. - P119-130 MeSH-главная: АКРОМЕГАЛИЯ -- ACROMEGALY (патофизиология) Аннотация: Acromegaly (ACRO) is a rare disease of an excessive somatic growth and distorted proportions arising from hypersecretion of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Insidious clinical mani­festation of the GH excess, resulting from a GH-secreting pituitary adenoma, renders ACRO as the disease with a typically delayed diagnosis, approximately 10 years from the symptoms onset. Despite the increasing availability of modern diagnostic methods, the timely diagnosis of ACRO at present is still a problem which is directly connected with the further prognosis. Owing to this reasons, it is important to establish national registers of patients with hormonally active pituitary adenomas, including registers of patients with ACRO. But not all countries have the possibility to create such registries at the state level. In the countries of Eastern Europe, the research of the kind is carried out in the specialized national medical centers The aim of this study is to investigate basic demographic parameters such as the age and gender related features, age at diagnosis of the disease, its clinical manifestations, biochemical control and structure of compli­cations in Ukrainian patients with ACRO in a single neuroendocrinological centre. Material and methods. Patients with acromegaly, including somatotropinoma (ST) and somatomam­motropinoma (SMT): the data collected within the Neuroendocrinological Centre, based in V. Danilevsky’ Institute for Endocrine Pathology Problems (n = 133 [including 47 de novo]: female — 88, male — 45) and retrospective study 133 patients (female — 91, male — 42) who had neurosurgical treatment (according to da­tabase of Romonadov’ Neurosurgery Institute). Diagnosis of ACRO was based on the Consensus Statement on acromegaly (2014). The levels of PRL, GH and IGF-1 were measured. All patients underwent an enhanced and a plain MRI scan using a Siemens 1.5 T MRI. Statistical analysis: SPSS 19.0 statistical software (IBM Corp., Armonk, NY, US) was used for statistical analysis. Comparisons between plasma GH and IGF-1 levels of patients in two groups were done by ANOVA for age, gender, and other hormonal and clinical parameters Доп.точки доступа: Khyzhnyak, O. Mykytyuk, M. Guk, M. Nikolaiev, R. Gogitidze, T. Свободных экз. нет